Clopidogrel and Ticlopidene Cross-reactivity–Induced Erythroderma Following Drug-Eluting Stenting

Erythroderma,a potentially fatal dermatologic emergency, is a scaling erythematous eruption involving 90% or more of the cutaneous surface. Psoriasis, mycosis fungoides, Sézary syndrome, and atopic dermatitis may culminate in the presentation of erythroderma. Several drugs also have been implicated. A thienopyridine derivative, such as clopidogrel or ticlopidine, in combination with aspirin is the gold standard of care after percutaneous coronary intervention (PCI) with stenting. We present a patient with cross-reactivity to clopidogrel and ticlopidine who developed erythroderma after undergoing drug-eluting stent (DES) implantation.